Description
Retatrutide (LY3437943) is a novel triagonist peptide that activates GLP-1, GIP, and glucagon receptors. It is studied for its profound effects on weight management, glucose control, and metabolic health, representing one of the most advanced incretin-based therapies in development.
Benefits
- Weight management — studied for dramatic body weight reductions in phase 2 trials.
- Glucose control — linked to improved HbA1c and insulin sensitivity in type 2 diabetes.
- Metabolic health — explored for cholesterol, liver fat reduction, and energy regulation.
- Triple pathway synergy — combines GLP-1, GIP, and glucagon receptor activity.
- Next-gen incretin — developed as a cutting-edge obesity and diabetes research tool.
What researchers look at
- Triagonist activity: simultaneous activation of GLP-1, GIP, and glucagon receptors.
- Phase 2 clinical trials reporting unmatched weight loss efficacy.
- Head-to-head comparisons with semaglutide and tirzepatide.
- Exploration of cardiometabolic, hepatic, and long-term safety outcomes.
Quick Specs
- Form: Lyophilized peptide
- Net per vial: 10 mg
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
Identity Basics
- Type: Triple GLP-1/GIP/glucagon receptor agonist
- Formula / M.W.: Peptide analog (varies by formulation)
- CAS: 2381089-83-2
Selected Research
- PubChem entry — chemical identity:
https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide
- Phase 2 obesity trial (NEJM, 2023):
https://pubmed.ncbi.nlm.nih.gov/37323486/
- Mechanism review — triple agonism:
https://pubmed.ncbi.nlm.nih.gov/36006191/
- Comparisons with GLP-1/GIP agonists:
https://pubmed.ncbi.nlm.nih.gov/37323485/
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
Even if the vial label or product image states a certain concentration, always go by the COA for the true value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or picture indicates.
Janoshik COA – Third-Party Testing
https://janoshik.com/tests/77993-Retatrutide_ZNN8TNSJP1DK – September 9 2025
https://verify.janoshik.com/tests/100700-Retatrutide_10mg_VPeptide_Canada_YP5VUQ2Y8RGT – January 19 2026
